Efficacy of a mucoadhesive patch compared with an oral solution for treatment of aphthous stomatitis

Drugs in R and D

Volumn 9, Issue 1, 2008, Pages 29-35

  Shemer, Avner ^a   Amichai, Boaz ^b   Trau, Henri ^a   Nathansohn, Nir ^a   Mizrahi, Boaz ^c   Domb, Abraham J ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Aphthous ulcer, treatment; Drug delivery systems

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CANKER COVER; CORTICOSTEROID; KANK A; NEUROLEPTIC AGENT; RETINOID; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; APHTHOUS STOMATITIS; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT WITHDRAWAL;

EID: 37549009859     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200809010-00003     Document Type: Article

References (28)

1. Scully C. Aphthous ulceration. N Engl J Med 2006; 355 (2): 165-72
2. Stone OJ. Aphthous stomatitis (canker sores): a consequence of high oral submucosal viscosity (the role of extracellular-matrix and the possible role of lectins). Med Hypotheses 1991; 36 (4): 341-4
3. Zunt SL. Recurrent aphthous stomatitis. Dermatol Clin 2003 Jan; 21 (1): 33-39
4. Woodley J. Bioadhesion: new possibilities for drug administration? Clin Pharmacokinet 2001; 40 (2): 77-84
5. Plemons JM, Rees TD, Binnie WH, et al. Evaluation of acemannan in the treatment of recurrent aphthous stomatitis. Wounds 1994; 6: 40-5
6. Ship JA, Chavez EM, Doerr PA, et al. Recurrent aphthous stomatitis. Quintessence Int 2000; 31 (2): 95-112
7. Vincent SD, Lilly GE. Clinical, historic, and therapeutic features of aphthous stomatitis: literature review and open clinical trial employing steroids. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1992; 74: 79-86
8. Pedersen A. Psychologic stress and recurrent aphthous ulceration. J Oral Pathol Med 1989; 18 (2): 119-22
9. Nolan A, Lamey PJ, Milligan KA, et al. Recurrent aphthous ulceration and food sensitivity. J Oral Pathol Med 1991; 20 (10): 473-5
10. Brokstad B, Barkvoll P. The effect of two toothpaste detergents on the frequency of recurrent aphthous ulcers. Acta Odontol Scand 1996; 54 (3): 150-3
11. Natah SS, Hayrinen-Immonen R, Hietanen J, et al. Immunolocalization of tumor necrosis factor-alpha expressing cells in recurrent aphthous ulcer lesions (RAU). J Oral Pathol Med 2000; 29 (1): 19-25
12. Porter SR, Hegarty A, Kaliakatsou F, et al. Recurrent aphthous stomatitis. Clin Dermatol 2000; 18 (5): 569-78
13. Khandwala A, VanInwegen RG, Alfano MC. 5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: 1. Clinical demonstration of acceleration of healing and resolution of pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 83 (2): 222-30
14. Nagai T, Machida Y. Buccal delivery systems using hydrogels. Adv Drug Delivery Rev 1993; 11 (1-2): 179-91
15. Shojaei AH, Paulson J, Honary S. Evaluation of poly(acrylic acid-co-ethylhexyl acrylate) films for mucoadhesive transbuccal drug delivery: factors affecting the force of mucoadhesion. J Control Release 2000; 67 (2-3): 223-32
16. Mizrahi B, Golenser J, Wolnerman JS, et al. Adhesive tablet effective for treating canker sores in humans. J Pharm Sci 2004; 93 (12): 2927-35
17. Mizrahi B, Shapira L, Domb AJ, et al. Citrus oil and MgCl2 as antibacterial and anti-inflammatory agents. J Periodont 2006; 77 (6): 963-8
18. Houri-Haddad Y, Soskolne WA, Halabi A, et al. Repeat bacterial challenge in a subcutaneous chamber model results in augmented tumour necrosis factor-alpha and interferon-gamma response, and suppression of interleukin-10. Immunology 2000; 99 (2): 215-20
19. Cianciola JA, Algieri ML, Bush P, et al. Duration and intensity of anesthetic effect produced by Canker Sore Medications. J Clin Dentistry 1997; 8 (4): 100-2
20. Nagai T, Machida Y. Advances in drug delivery: mucosal adhesive dosage forms. Pharm Internat 1985; 8: 196-200
21. Kutcher MJ, Ludlow JB, Samuelson AD, et al. Evaluation of a bioadhesive device for the management of aphthous ulcers. J Am Dent Assoc 2001; 132 (3): 368-76
22. Bravo-Osuna I, Vauthier C, Farabollini A, et al. Mucoadhesion mechanism of chitosan and thiolated chitosan-poly(isobutyl cyanoacrylate) core-shell nanoparticles. Biomaterials 2007; 28 (13): 2233-43
23. Bernkop-Schnurch A, Guggi D, Pinter Y. Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J Control Release 2004; 94 (1): 177-86
24. Bernkop-Schnurch A, Kast CE. Chemically modified chitosans as enzyme inhibitors. Adv Drug Deliv Rev 2001; 52 (2): 127-37
25. Stoy PJ. The use of topical application in the treatment of inflammatory conditions of the oral mucosa. Dent Practice 1966; 16: 444-7
26. Browne RM, Fox EC, Anderson RJ. Topical triamcinolone in recurrent aphthous stomatitis. Lancet 1968; 16: 565-7
27. Dale RA, Berrong JM, Sandoval VA, et al. The use of ORA 5 on recurrent aphthous ulcers. Gen Dent 1989; Nov-Dec: 504-7
28. Natah SS, Konttinen YT, Enattah NS, et al. Recurrent aphthous ulcers today: a review of the growing knowledge. Int J Oral Maxillofac Surg 2004; 33 (3): 221-34